Skip to main content
Terug
INSM logo

Insmed Incorporated

Datakwaliteit: 100%
INSM
NASDAQ Healthcare Biotechnology
€ 139,14
▼ € 4,84 (-3,36%)
Marktkapitalisatie: 29,99B
Dagbereik
€ 137,20 € 145,52
52-Weeksbereik
€ 60,40 € 212,75
Volume
2.716.968
50D / 200D Gem.
€ 152,68 / € 147,77
Vorige Slotkoers
€ 143,98

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E -23,5 0,4
P/B 40,6 2,9
ROE % -249,3 3,7
Net Margin % -210,5 3,9
Rev Growth 5Y % 33,9 10,0
D/E 1,0 0,2

Koersdoel Analisten

Hold
€ 214,47 +54.1%
Low: € 166,00 High: € 269,00
Forward WPA
-€ 2,72
Omzet Sch.
1,7 B

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 11,07
€ 8,40 – € 14,24
6,5 B 6
FY2029 € 8,48
€ 6,44 – € 10,91
5,2 B 10
FY2028 € 3,97
€ 0,90 – € 7,23
3,9 B 15

Belangrijkste Punten

Revenue grew 33,93% annually over 5 years — strong growth
Negative free cash flow of -967,58M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 32,80%
Capital efficient — spends only 5,37% of revenue on capex

Groei

Revenue Growth (5Y)
33,93%
Revenue (1Y)66,73%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-249,28%
ROIC-58,56%
Net Margin-210,54%
Op. Margin-194,04%

Veiligheid

Debt / Equity
1,04
Current Ratio3,83
Interest Coverage-14,04

Waardering

P/E Ratio
-23,49
P/B Ratio40,59
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 66,73% Revenue Growth (3Y) 40,96%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 33,93% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 606,42M Net Income (TTM) -1,28B
ROE -249,28% ROA -56,38%
Gross Margin 79,41% Operating Margin -194,04%
Net Margin -210,54% Free Cash Flow (TTM) -967,58M
ROIC -58,56% FCF Growth (3Y) N/A
Safety
Debt / Equity 1,04 Current Ratio 3,83
Interest Coverage -14,04 Dividend Yield 0,00%
Valuation
P/E Ratio -23,49 P/B Ratio 40,59
P/S Ratio 49,46 PEG Ratio -1,93
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 29,99B Enterprise Value 30,25B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 606,42M 363,71M 305,21M 245,36M 188,46M
Net Income -1,28B -913,77M -749,57M -481,53M -434,65M
EPS (Diluted) -6,41 -5,57 -5,34 -3,91 -3,88
Gross Profit 481,55M 277,97M 239,64M 190,23M 144,31M
Operating Income -1,18B -878,25M -709,63M -457,32M -375,09M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 2,26B 2,03B 1,33B 1,66B 1,24B
Total Liabilities 1,53B 1,74B 1,66B 1,57B 833,04M
Shareholders' Equity 738,98M 285,38M -331,92M 87,95M 410,47M
Total Debt 768,16M 1,31B 1,20B 1,18B 612,27M
Cash & Equivalents 510,45M 555,03M 482,37M 1,07B 716,78M
Current Assets 1,79B 1,62B 929,06M 1,27B 837,04M
Current Liabilities 468,87M 297,53M 225,63M 190,24M 135,17M